Skip to content

CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage

CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05093725
Enrollment
10
Registered
2021-10-26
Start date
2021-11-30
Completion date
2022-06-30
Last updated
2021-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Umbilical Cord of Normal Labor

Brief summary

Human mesenchymal stem cells (MSCs) due to their regenerative and immunomodulatory properties are widely used for the treatment of bone and cartilage damage, cardiovascular, gastrointestinal, autoimmune, neurodegenerative diseases and cancer .It is shown that the use of MSCs in therapy is safe and can be effective .In 2006, the International Society for Cellular Therapy (ISCT) proposed the minimal criteria to define human MSCs. First, MSCs must be plastic-adherent when maintained in the standard culture conditions. Second MSCs must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface molecules.

Interventions

DEVICEflow cytomery

take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Days to No maximum
Healthy volunteers
Yes

Inclusion criteria

normal babies delivered by normal labor

Exclusion criteria

diseased or congenital anomalies

Design outcomes

Primary

MeasureTime frameDescription
evaluation the best passage of MSC culture by CD49 surface marker7 monthsevaluation the best passage of MSC culture by CD49 surface marker

Countries

Egypt

Contacts

Primary Contactsamia s shawky, resident
samya_dematri@med.sohag.edu.eg01280055734
Backup ContactHasnaa A Abo-elwafa

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026